Xeris Biopharma Holdings, Inc.
XERS
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.5B
$8.53
▼ -0.70%
P/E
-83.30
Mkt Cap
$1.5B
52-Wk Range
$5.25–$10.08
52-Week Range
$5.25 - $10.08
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 9.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary XeriSol and XeriJect formulation technology platforms enabling differentiated drug delivery
- First-mover advantage with Gvoke ready-to-use liquid glucagon in emergency hypoglycemia treatment
- Diversified portfolio across three FDA-approved therapies addressing distinct therapeutic areas with limited competition
- Established commercial infrastructure and regulatory expertise in specialty pharmaceutical markets
Bear Case
1 risk
- Average volatility.
Growth
Moderate growth ahead
Expansion of Gvoke into new indications and increased market penetration in severe hypoglycemia management
Value
Trading at 0.0x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Hot
+36.7% over 3m
Quality
Excellent
High-growth business (36% revenue growth, 83% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying XERS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of -$0.18 vs $0.01 consensus (-1582.7% surprise). Revenue of $91.0M vs $90.1M expected (+1.0%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-1582.7%
Revenue trend · last 8Q
—
+35%
+48%
+49%
+37%
+43%
+38%
+29%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$54.3M
$60.1M
$60.1M
$71.5M
$74.4M
$85.8M
$83.1M
$92.1M
Margins · last 8Q
Gross
86.4%
Operating
5.6%
Profit
-33.8%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Barclays · Aug 20, 2026
vs Industry
How XERS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related